Chemotherapy response and resistance

Current Opinion in Genetics and Development

Volumn 13, Issue 1, 2003, Pages 90-96

  Lee, Soyoung ^a   Schmitt, Clemens A ^a  

^a HUMBOLDT UNIVERSITY   (Germany)

Author keywords

[No Author keywords available]

Indexed keywords

ANTINEOPLASTIC AGENT;

APOPTOSIS; CANCER; CANCER CHEMOTHERAPY; CARCINOGENICITY; CELL AGING; CELL CYCLE; CELLULAR IMMUNITY; DRUG MECHANISM; DRUG RESPONSE; DRUG SCREENING; GENE MUTATION; HUMAN; ONCOGENE; PRIORITY JOURNAL; REVIEW; TREATMENT OUTCOME;

EID: 0037309193     PISSN: 0959437X     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0959-437X(02)00014-X     Document Type: Review

References (54)

1. Johnstone R.W., Ruefli A.A., Lowe S.W. Apoptosis: a link between cancer genetics and chemotherapy. Cell. 108:2002;153-164.
2. Melo J., Toczyski D. A unified view of the DNA-damage checkpoint. Curr. Opin. Cell. Biol. 14:2002;237-245.
3. Bosanquet A.G., Sturm I., Wieder T., Essmann F., Bosanquet M.I., Head D.J., Dorken B., Daniel P.T. Bax expression correlates with cellular drug sensitivity to doxorubicin, cyclophosphamide and chlorambucil but not fludarabine, cladribine or corticosteroids in B cell chronic lymphocytic leukemia. Leukemia. 16:2002;1035-1044.
4. Friesen C., Herr I., Krammer P.H., Debatin K.M. Involvement of the CD95 (APO-1/FAS) receptor/ligand system in drug-induced apoptosis in leukemia cells. Nat. Med. 2:1996;574-577.
5. Belka C., Schmid B., Marini P., Durand E., Rudner J., Faltin H., Bamberg M., Schulze-Osthoff K., Budach W. Sensitization of resistant lymphoma cells to irradiation-induced apoptosis by the death ligand TRAIL. Oncogene. 20:2001;2190-2196.
6. Wang C.Y., Mayo M.W., Korneluk R.G., Goeddel D.V., Baldwin A.S. Jr. NF-κB antiapoptosis: induction of TRAF1 and TRAF2 and c-IAP1 and c-IAP2 to suppress caspase-8 activation. Science. 281:1998;1680-1683.
7. Lee J.T. Jr., McCubrey J.A. The Raf/MEK/ERK signal transduction cascade as a target for chemotherapeutic intervention in leukemia. Leukemia. 16:2002;486-507.
8. Robles S.J., Adami G.R. Agents that cause DNA double strand breaks lead to p16INK4a enrichment and the premature senescence of normal fibroblasts. Oncogene. 16:1998;1113-1123.
9. 1 arrest checkpoint in response to DNA damage. Mol. Cell. Biol. 18:1998;378-387.
10. Suzuki K., Mori I., Nakayama Y., Miyakoda M., Kodama S., Watanabe M. Radiation-induced senescence-like growth arrest requires TP53 function but not telomere shortening. Radiat. Res. 155:2001;248-253.
11. INK4a correlates with the SA-β-Gal status following drug therapy.
12. INK4a control drug-induced senescence, and defects at the INK4a/ARF locus as a byproduct of ARF loss or selection against p53 during tumor development may provide the basis for compromised drug responses.
13. Serrano M., Lin A.W., McCurrach M.E., Beach D., Lowe S.W. Oncogenic ras provokes premature cell senescence associated with accumulation of p53 and p16INK4a. Cell. 88:1997;593-602.
14. Ferbeyre G., de Stanchina E., Querido E., McCurrach M.E., Hannon G., Lowe S.W. Oncogenic ras and p53 cooperate to induce cellular senescence. Mol. Cell. Biol. 22:2002;3497-3508 Introduction of oncogenic Ras cooperates with p53 to induce premature senescence in the presence of ARF. Activation of a temperature-sensitive p53 allele alone or the mere stabilization of p53 via ARF is insufficient to induce senescence, but contributes to the senescent phenotype in concert with qualitative changes mediated by oncogenic Ras.
15. Shelton D.N., Chang E., Whittier P.S., Choi D., Funk W.D. Microarray analysis of replicative senescence. Curr. Biol. 9:1999;939-945.
16. Dulic V., Beney G.E., Frebourg G., Drullinger L.F., Stein G.H. Uncoupling between phenotypic senescence and cell cycle arrest in aging p21-deficient fibroblasts. Mol. Cell. Biol. 20:2000;6741-6754.
17. Jain M., Arvanitis C., Chu K., Dewey W., Leonhardt E., Trinh M., Sundberg C.D., Bishop J.M., Felsher D.W. Sustained loss of a neoplastic phenotype by brief inactivation of MYC. Science. 297:2002;102-104.
18. L allows rapid Myc-driven tumor formation, thereby supporting the concept of oncogenic action and cellular failsafe reaction.
19. Hueber A.O., Zornig M., Lyon D., Suda T., Nagata S., Evan G.I. Requirement for the CD95 receptor-ligand pathway in c-Myc-induced apoptosis. Science. 278:1997;1305-1309.
20. Palmero I., Pantoja C., Serrano M. p19ARF links the tumor suppressor p53 to Ras. Nature. 395:1998;125-126.
21. Zindy F., Eischen C.M., Randle D.H., Kamijo T., Cleveland J.L., Sherr C.J., Roussel M.F. Myc signaling via the ARF tumor suppressor regulates p53-dependent apoptosis and immortalization. Genes Dev. 12:1998;2424-2433.
22. Fearnhead H.O., McCurrach M.E., O'Neill J., Zhang K., Lowe S.W., Lazebnik Y.A. Oncogene-dependent apoptosis in extracts from drug-resistant cells. Genes Dev. 11:1997;1266-1276.
23. Mendelsohn A.R., Hamer J.D., Wang Z.B., Brent R. Cyclin D3 activates Caspase 2, connecting cell proliferation with cell death. Proc. Natl. Acad. Sci. USA. 99:2002;6871-6876.
24. Moroni M.C., Hickman E.S., Denchi E.L., Caprara G., Colli E., Cecconi F., Muller H., Helin K. Apaf-1 is a transcriptional target for E2F and p53. Nat. Cell. Biol. 3:2001;552-558.
25. Muller H., Bracken A.P., Vernell R., Moroni M.C., Christians F., Grassilli E., Prosperini E., Vigo E., Oliner J.D., Helin K. E2Fs regulate the expression of genes involved in differentiation, development, proliferation, and apoptosis. Genes Dev. 15:2001;267-285.
26. Nahle Z., Polyakova J., McCurrach M.E., Davuluri R.V., Narita M., Jacobson M.D., Zhang M.Q., Lazebnik Y., Bar-Sagi D., Lowe S.W. Direct coupling of the cell cycle and cell death machinery by E2F. Nat. Cell. Biol. 4:2002;859-864.
27. Rowland B.D., Denissov S.G., Douma S., Stunnenberg H.G., Bernards R., Peeper D.S. E2F transcriptional repressor complexes are critical downstream targets of p19(ARF)/p53-induced proliferative arrest. Cancer Cell. 2:2002;55-65 De-repression, not activation, is the predominant mechanism increasing the expression of E2F target genes. This de-repression also renders mouse embryo fibroblasts resistant to the pro-senescent capabilities of ARF, p53 or oncogenic Ras, which identifies E2F transcriptional repressor complexes as downstream effectors of anti-proliferative ARF/p53 signaling.
28. Yoshikawa R., Kusunoki M., Yanagi H., Noda M., Furuyama J.I., Yamamura T., Hashimoto-Tamaoki T. Dual antitumor effects of 5-fluorouracil on the cell cycle in colorectal carcinoma cells: a novel target mechanism concept for pharmacokinetic modulating chemotherapy. Cancer Res. 61:2001;1029-1037.
29. Schmitt C.A., Rosenthal C.T., Lowe S.W. Genetic analysis of chemoresistance in primary murine lymphomas. Nat. Med. 6:2000;1029-1035.
30. Schmitt C.A., Wallace-Brodeur R.R., Rosenthal C.T., McCurrach M.E., Lowe S.W. DNA damage responses and chemosensitivity in the Eμ-myc mouse lymphoma model. Cold Spring Harb. Symp. Quant. Biol. 65:2000;499-510.
31. Schmitt C.A., Lowe S.W. Apoptosis and chemoresistance in transgenic cancer models. J. Mol. Med. 80:2002;137-146.
32. Schmitt C.A., McCurrach M.E., de Stanchina E., Wallace-Brodeur R.R., Lowe S.W. INK4a/ARF mutations accelerate lymphomagenesis and promote chemoresistance by disabling p53. Genes Dev. 13:1999;2670-2677.
33. Shipp M.A., Ross K.N., Tamayo P., Weng A.P., Kutok J.L., Aguiar R.C., Gaasenbeek M., Angelo M., Reich M., Pinkus G.S.et al. Diffuse large B-cell lymphoma outcome prediction by gene-expression profiling and supervised machine learning. Nat. Med. 8:2002;68-74 On the basis of a combined microarray technology and a supervised learning approach to investigating primary tumor samples from untreated patients, this study demonstrates that the status of a small number of genes, including genes controlling apoptosis, is sufficient to predict treatment outcome in diffuse large-B-cell lymphoma. This study underlines by genetic means the role of drug-induced apoptosis as a pivotal program not only for acute anti-tumor activity, but also for long-term prognosis in patients.
34. Sander C.A., Yano T., Clark H.M., Harris C., Longo D.L., Jaffe E.S., Raffeld M. p53 mutation is associated with progression in follicular lymphomas. Blood. 82:1993;1994-2004.
35. Dimri G.P., Lee X., Basile G., Acosta M., Scott G., Roskelley C., Medrano E.E., Linskens M., Rubelj I., Pereira-Smith O.et al. A biomarker that identifies senescent human cells in culture and in aging skin in vivo. Proc. Natl. Acad. Sci. USA. 92:1995;9363-9367.
36. Chang B.D., Xuan Y., Broude E.V., Zhu H., Schott B., Fang J., Roninson I.B. Role of p53 and p21waf1/cip1 in senescence-like terminal proliferation arrest induced in human tumor cells by chemotherapeutic drugs. Oncogene. 18:1999;4808-4818.
37. Chang B.D., Swift M.E., Shen M., Fang J., Broude E.V., Roninson I.B. Molecular determinants of terminal growth arrest induced in tumor cells by a chemotherapeutic agent. Proc. Natl. Acad. Sci. USA. 99:2002;389-394 A gene-expression comparison between the senescent and the proliferating fractions of a drug-treated human colon cancer cell line demonstrates that drug-induced senescence is associated with reduced expression of genes involved in proliferation, and with increased expression of genes encoding intracellular and secreted growth inhibitors, suggesting that paracrine effects might be important in drug-induced senescence.
38. Metz T., Harris A.W., Adams J.M. Absence of p53 allows direct immortalization of hematopoietic cells by the myc and raf oncogenes. Cell. 82:1995;29-36.
39. Kamijo T., van de Kamp E., Chong M.J., Zindy F., Diehl J.A., Sherr C.J., McKinnon P.J. Loss of the ARF tumor suppressor reverses premature replicative arrest but not radiation hypersensitivity arising from disabled atm function. Cancer Res. 59:1999;2464-2469.
40. INK4amight act as the key mechanism that unlocks Ras-driven tumorigenesis.
41. Hsu B., Marin M.C., el-Naggar A.K., Stephens L.C., Brisbay S., McDonnell T.J. Evidence that c-myc mediated apoptosis does not require wild-type p53 during lymphomagenesis. Oncogene. 11:1995;175-179.
42. Chin L., Pomerantz J., Polsky D., Jacobson M., Cohen C., Cordon-Cardo C., Horner J.W. II, DePinho R.A. Cooperative effects of INK4a and ras in melanoma susceptibility in vivo. Genes Dev. 11:1997;2822-2834.
43. Lin A.W., Lowe S.W. Oncogenic ras activates the ARF-p53 pathway to suppress epithelial cell transformation. Proc. Natl. Acad. Sci. USA. 98:2001;5025-5030.
44. Strasser A., Harris A.W., Bath M.L., Cory S. Novel primitive lymphoid tumors induced in transgenic mice by cooperation between myc and bcl-2. Nature. 348:1990;331-333.
45. Eischen C.M., Weber J.D., Roussel M.F., Sherr C.J., Cleveland J.L. Disruption of the ARF-Mdm2-p53 tumor suppressor pathway in Myc-induced lymphomagenesis. Genes Dev. 13:1999;2658-2669.
46. +/- haematopoietic stem cells that are otherwise prone to p53 inactivation can prevent p53 loss, but results in lymphomas that are as aggressive as their p53-deficient counterparts, although the Bcl2-expressing group preserves other important p53 effector functions such as checkpoint control or chromosomal stability.
47. INK4a can act as tumor suppressors in mice, although this depends upon the genetic and cell-type context.
48. Carter T.L., Watt P.M., Kumar R., Burton P.R., Reaman G.H., Sather H.N., Baker D.L., Kees U.R. Hemizygous p16(INK4A) deletion in pediatric acute lymphoblastic leukemia predicts independent risk of relapse. Blood. 97:2001;572-574.
49. Javelaud D., Besancon F. Inactivation of p21WAF1 sensitizes cells to apoptosis via an increase of both p14ARF and p53 levels and an alteration of Bax/Bcl-2 ratio. J. Biol. Chem. 277:2002;37949-37954.
50. Foster B.A., Coffey H.A., Morin M.J., Rastinejad F. Pharmacological rescue of mutant p53 conformation and function. Science. 286:1999;2507-2510.
51. Morris M.J., Tong W.P., Cordon-Cardo C., Drobnjak M., Kelly W.K., Slovin S.F., Terry K.L., Siedlecki K., Swanson P., Rafi M.et al. Phase I trial of BCL-2 antisense oligonucleotide (G3139) administered by continuous intravenous infusion in patients with advanced cancer. Clin. Cancer Res. 8:2002;679-683.
52. Bykov V.J., Issaeva N., Shilov A., Hultcrantz M., Pugacheva E., Chumakov P., Bergman J., Wiman K.G., Selivanova G. Restoration of the tumor suppressor function to mutant p53 by a low-molecular-weight compound. Nat. Med. 8:2002;282-288.
53. Fulda S., Wick W., Weller M., Debatin K.M. Smac agonists sensitize for Apo2L/TRAIL- or anticancer drug-induced apoptosis and induce regression of malignant glioma in vivo. Nat. Med. 8:2002;808-815.
54. Bassi L., Carloni M., Fonti E., Palma de la Pena N., Meschini R., Palitti F. Pifithrin-alpha, an inhibitor of p53, enhances the genetic instability induced by etoposide (VP16) in human lymphoblastoid cells treated in vitro. Mutat. Res. 499:2002;163-176.